Bleomycin Sulfate

For research use only. Not for use in humans.

製品コードS1214 別名：NSC125066

分子量(MW)：1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ

価格(税別)

在庫

10mg	JPY 30200	あり
50mg	JPY 113200	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(36)

質量管理及び製品安全説明書

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

生物活性

製品説明

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. ^[1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. ^[2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. ^[3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. ^[4]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
F98	M4H2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nndFDjiJNzMECwJO69dQ>?	NXXTR\|RlOjRiaNMg	MkTubY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NF\P[nczPjB6OEexNS=>
POLK WT	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIfYeHJKSzVyPUGxMlfjiIoEsfMAjVEvP8LizszN	NIixPWczPjB\|MUSwNC=>
POLK KO	NUm3NGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUDJR\|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?=	MUmyOlA{OTRyMB?=
POLK CD	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGjtN5ZKSzVyPUWuOVnjiIoEsfMAjVEvODEEoN88US=>	NUmyfXBbOjZyM{G0NFA>
RLE/Abca3	MXTGeY5kfGmxbjDBd5NigQ>?	MmnBNE41yqEQvF2=	M1TpWlE1PMLiaB?=	NG\ob\|VqdmS3Y3XzJIEhdW:{cHjvcI9ocWOjbDDjbIFv\2ViZoLvcUBmeGm2aHXsbYFtNWyra3WgcY9zeGixbH;nfUB1dyCjIIfp[IUtKHOycnXh[E1wfXRibX;ydIhwdG:pedMg	M2jhbVI2PzZyNUO4
PMCs	MnTnSpVv[3Srb36gRZN{[Xl?	NX3ad\|FDOC5z4pETNuKh\|rypL33s	MmfPNlTDqGh?	Mk[4Z4F2e2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi	NUS1T3FYOjV3OUW2OFI>
PMCs	NWKx[2dDTnWwY4Tpc44hSXO\|YYm=	NYnUcnNEOC5{wrFOwIcwdWx?	NGfrcI0zPOLCk{eyxsBp	NXz0R4tTcW6mdXPld{BqdmO{ZXHz[ZMhcW5idnnt[Y51cW5iYX7kJO6yNVOPQTDwdo91\Wmw	MnHVNlU2QTV4NEK=
PMCs	NF3ndIJHfW6ldHnvckBCe3OjeR?=	NUjvUYV3OC5{wrFOwIcwdWx?	MliyO\|IhcA>?	M2jDXYlv\HWlZYOg[IVkemWjc3XzJIlvKGO7dH;r[ZJifGmwLUigZY5lKEVvY3HkbIVzcW5icILveIVqdg>?	M1zyR\|I2PTl3NkSy
PMCs	NF\4boxHfW6ldHnvckBCe3OjeR?=	MnToNE4zyqEQvHevcYw>	MX6xNk8zPC92ODDo	M1\0ZYlv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?=	M2\zN\|I2PTl3NkSy
IMR-32	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor3O{426ojUMUKwJOK2\y:vbB?=	MWKxNwKJmjR6IHi=	MXjJR\|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v	NGK1WWszPTV\|NkO0OS=>
HT1080	NWG1cmloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVWxJO69VQ>?	MnPDNlQhcMLi	MWrs[YFleyC2bzDhJGczN01iZHXsZZk>	NWnycoVmOjV3MUi5OlE>
HT1080	MV3GeY5kfGmxbjDBd5NigQ>?	NFnkXnAyKM7:TR?=	MYCyOEBpyqB?	MYLpcoR2[2W\|IHGgdI91\W62IHfsc4JidCCGTlGg[IFu[WenIILld5BwdnOn	MkXiNlU2OTh7NkG=
HDFn	NHjVeFREgXSxdH;4bYNqfHliQYPzZZk>		M{jDOlczKGh?	NGXXXFhKSzVyPUmuN\|EmyqB?	MWmyOVI4Pjd7Mh?=
THP-1	NHnDendEgXSxdH;4bYNqfHliQYPzZZk>		NGTjZZU4OiCq	Ml;DTWM2OD12Lke3KS=>	MVWyOVI4Pjd7Mh?=
HT-29	MkPVR5l1d3SxeHnjbZR6KEG\|c3H5		NV;NfoZuPzJiaB?=	MlriTWM2OD1zMT60PUU>	M1fJVVI2Ojd4N{my
HCT116	NVPZTJFMS3m2b4TvfIlkcXS7IFHzd4F6		MljyO\|IhcA>?	NIq5RodKSzVyPUGxMlM1LQ>?	M2rxdFI2Ojd4N{my
A431	NX3aWZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zR[\|UxNTJyMDDJWS=>	M3y5fVQ56oDLaB?=	NV\0bnRPcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	NUe1S5kyOjVzMEGyPVk>
T24	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnscpN4PTBvMkCwJGlW	MYK0PQKBkWh?	NXnx[lFVcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	MoP1NlUyODF{OUm=
AY-27	NITNO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;sfFN5PTBvMkCwJGlW	NF3KTJg1QOLCiXi=	NEX0WIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	MlrxNlUyODF{OUm=
A549	M2qwPWZ2dmO2aX;uJGF{e2G7	NFvpZpAyKML3Zz;tUOKh	M1nkZlAuPDhiaB?=	MYnpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=>	M3fVdVI1QTZ\|NkO1
MLE12	NVXLS\|Z6TnWwY4Tpc44hSXO\|YYm=	M2jscVEhyrWpL33MxsA>	MVWwMVQ5KGh?	MXrpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=>	NVvuOFF[OjR7NkO2N\|U>
Jurkat	NFr2e25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXTNlDjiIoQvH2=	MYSyOQKBkWkEoB?=	MYrhdpJme3S\|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=>	NUXmSld2OjR7MU[4PVM>
HeLa	NXPwZ5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEfB[FNKSzVyPUGwMlLDqM7:TR?=	M3;3UlI1PzN{M{m3
C18-4	NWLVNI5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrJU3AxNTFyMDFOwG0>		MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NXLnVYhVOjR3N{G5PFI>
BMG-1	NIjofYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnGxOFAwQDEEoN88[{9u	MoDEN:KhcA>?	MkfibY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MWWyN\|kxPjd{Nh?=
A459	NGPne3VCeG:ydH;zbZMhSXO\|YYm=	Mk\jNVAhdVV?	MnnwOFghcA>?	M4TFT4lv\HWlZYOgZZBweHSxc3nz	MlzpNlM6ODJ5Nk[=
MOCK	MVLBdI9xfG:\|aYOgRZN{[Xl?	NXHpXGs4OTBibWW=	M{m2NVQ5KGh?	NEPyOYFqdmS3Y3XzJIFxd3C2b4Ppdy=>	MnHuNlM6ODJ5Nk[=
MMP1	MlnSRZBweHSxc3nzJGF{e2G7	Ml74NVAhdVV?	NYTyZ2V5PDhiaB?=	Ml3vbY5lfWOnczDhdI9xfG:\|aYO=	M1zLZlI{QTB{N{[2
A549	NGTkbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTye2pXOjByIN88US=>	NWTrfG5pOjRiaNMg	M1T3boRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	MlPuNlM5ODV5OUO=
HCT-116	MVfBdI9xfG:\|aYOgRZN{[Xl?	M4\wN\|MwPy53L{G1JO69\y:vbB?=	MVW0PEBp	MVPy[YR2[2W\|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u	NXK1WmJnOjN5MEi2Olg>
HeLa	NXPWTYRsSXCxcITvd4l{KEG\|c3H5	NFnGN4U{NzdwNT:xOUDPxGdxbXy=	MWC0PEBp	NHryWZhz\WS3Y3XzJJRp\SCuZY\lcEBw\iCETFigZZQhcGmpaDDjc45k\W62cnH0bY9v	M1\ORVI{PzB6Nk[4
HCT116	M3foeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED5OZQxNTFyMDFOwIcwdWx?	NIG3NHM1QCCq	NEjscGNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	M1PoWlI{PTF6MkCx
NCM460	NWfVUW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nvPFAuOTByIN88[{9udA>?	MYq0PEBp	MWnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NFjQOJYzOzVzOEKwNS=>
NT2	NF;uZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFTVTlczPCCqwrC=	MVXMSFUxRTRyMPMAjeK2\y:vbB?=	MojSNlM{QDZ2MkC=
NT2	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu0PEBp	NEjRTnBNTDVyPUGwNEDDvWdxbXy=	M3ewS\|I{Ozh4NEKw
NT2	M2KxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnTJO\|IhcA>?	MVfMSFUxRTJy4pEJxtVoN22u	MX[yN\|M5PjR{MB?=
NT2	MVjBdI9xfG:\|aYOgRZN{[Xl?	MmXzOFAx6oDLwsXnM41t	MYOyOEBpyqB?	MXjpcoR2[2W\|IIPp[45q\mmlYX70JIlv[3KnYYPld{BqdiClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA>	MW[yN\|M5PjR{MB?=
NTera-2	M1vYNmZ2dmO2aX;uJGF{e2G7	MU[xNlAh\|rypL33s	NF\4fVk4OiCq	M2DlT5Nq\26rZnnjZY51dHliaX7jdoVie2W\|IEitbZNweHKxc4ThcoUhdGW4ZXzz	NVHldGd2OjJ6MkWzOVU>
NCCIT	MnHkSpVv[3Srb36gRZN{[Xl?	MYqxNlAh\|rypL33s	MlfVO\|IhcA>?	NUfKV4xWe2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgPE1qe2:ycn;zeIFv\SCuZY\lcJM>	NVHu[HliOjJ6MkWzOVU>
NTera-2	MX\GeY5kfGmxbjDBd5NigQ>?	NUjURlh1OTJyIN88[{9udA>?	NUX3bJNOPzJiaB?=	NYrSN\|Z4e2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgWGJCWlNibHX2[Yx{	NV\IXGVbOjJ6MkWzOVU>
NCCIT	NEnufnpHfW6ldHnvckBCe3OjeR?=	NUSyRoFsOTJyIN88[{9udA>?	NUHKOHFSPzJiaB?=	MnPZd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz	M1fXT\|IzQDJ3M{W1
NCCIT	M4Dse2Z2dmO2aX;uJGF{e2G7	MmK2NVIxKM7:Zz;tcC=>	NU\WfZdFPzJiaB?=	NVn4RYFKe2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgS3NJKGyndnXsdy=>	MYqyNlgzPTN3NR?=
NTera-2	NVeyV\|B2TnWwY4Tpc44hSXO\|YYm=	M1f5OFEzOCEQvHevcYw>	NUPmPYt3PzJiaB?=	M3;qcJNq\26rZnnjZY51dHliaX7jdoVie2W\|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{	M{jldVIzQDJ3M{W1
NCCIT	MojESpVv[3Srb36gRZN{[Xl?	MVixNlAh\|rypL33s	NIP0cpQ4OiCq	NFfUXpp{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>?	M33Gc\|IzQDJ3M{W1
NTera-2	NGjGWFdHfW6ldHnvckBCe3OjeR?=	M{LqSlEzOCEQvHevcYw>	M4XRWlczKGh?	MUjzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy\|	NWTPUGppOjJ6MkWzOVU>
NCCIT	MkTJSpVv[3Srb36gRZN{[Xl?	NHPzPHkyOjBizsznM41t	M13qbFczKGh?	NG\Tcnh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz	MV[yNlgzPTN3NR?=
MDA-MB-468	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrZ[\|Ex6oDVMkCwxsDPxGdxbVy=	MX[yOEBp	NHzMZ5VqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	MmDuNlI5OTlzOU[=
231-H2N	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGG4[VAx6oDVMkCwxsDPxGdxbVy=	M3jkVlI1KGh?	M2jaO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	MlTnNlI5OTlzOU[=
A549	NEm2OI1HfW6ldHnvckBCe3OjeR?=	M{n6SlIxOC92MECg{txO		M13nUpJme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T	MX6yNlc4OzZ7Nx?=
A549	M3jkc2Z2dmO2aX;uJGF{e2G7	MoPMNE01ODBizszN	NIrpVW0zNTR6IHi=	NFTJO2Nk[XW\|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl	MUKyNlc4OzZ7Nx?=
A549	MWHGeY5kfGmxbjDBd5NigQ>?	M{HINVExOCEQvF5CpC=>	MkXjNQKBmzR6IHi=	NUX1[pc{[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v	NH\oUZczOjd5M{[5Oy=>
A549	NEG1V3lHfW6ldHnvckBCe3OjeR?=	M2\3WlExOCEQvF5CpC=>	NGTYPWYx6oDVNEigbC=>	NIjBd29k[XW\|ZYOgVGtFOSClbHXheoFo\Q>?	MV:yNlc4OzZ7Nx?=
A549	NEDMT5ZHfW6ldHnvckBCe3OjeR?=	NUnNPGZ7OTByIN88UeKh	NIDRZZQx6oDVNEigbC=>	MnXvZ4F2e2W\|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>?	MXmyNlc4OzZ7Nx?=
A549	M1LtdGZ2dmO2aX;uJGF{e2G7	MnnVNVAxKM7:TdMg	NV70bVhyOOLCk{S4JIg>	NWjtWYtW\GWlcnXhd4V{KE2PUDDhcoQhSVSSIHzleoVtew>?	MlfONlI4PzN4OUe=
MCF-7/Her-18	NGrue2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P1SlAvPDJvMUewNEDPxGdxbVy=	M2fDflI1KGh?	NFHub2xqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	Mn;tNlI3OjF2MES=
MCF-7	MVXQSHQwWEOLIGTy[YF1dWWwdB?=	NEm5WWoxNjJ3IN88[{9udC5?	NEDSOWUyNTRiaB?=	MV3zbI94eyC\|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0	MnLRNlI2QTF{OES=
MDA-MB-231	M4HUd3BFXC:SQ1mgWJJm[XSvZX70	Mnj1NE4zPSEQvHevcYwv	MXOxMVQhcA>?	NVzzcph{e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>?	NVPl[mx3OjJ3OUGyPFQ>
MDA-MB-235	NVGxUZpqWESWL2DDTUBVemWjdH3lcpQ>	MlPmNE4zPSEQvHevcYwv	NIC2XmoyNTRiaB?=	NWDXSmZKe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>?	NGDmNGYzOjV7MUK4OC=>
MCF-7	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1O2ZlAuOiEQvHevcYwv	NIfWWFczPC92ODDo	MYfFR\|UxRTFwMjFOwIcwdUx?	MXeyNlU6OTJ6NB?=
NCCIT	M1;GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXVUGIzOOLCk{G0NOKh\|rypL33s	NXm2bZZUPzJiaB?=	MnXiUGQ2OD1zMkFCpO69\y:vbNMg	NIfEfYYzOjV4MkG2NC=>
NCCIT	M3TlVmZ2dmO2aX;uJGF{e2G7		NGft[XY4OiCq	NX\CTJVNe2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zJIFkfGm4aYT5xsA>	NWPOdG8{OjJ3NkKxOlA>
NCCIT	MoTISpVv[3Srb36gRZN{[Xl?		MnjyO\|IhcA>?	MWLzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNThiYXP0bZZqfHoEoB?=	NUXUXWdrOjJ3NkKxOlA>
NCCIT	MUnGeY5kfGmxbjDBd5NigQ>?		Ml;5O\|IhcA>?	NIfQRWN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUmgZYN1cX[rdIpCpC=>	NEHT[4QzOjV4MkG2NC=>
NCCIT	MVPGeY5kfGmxbjDBd5NigQ>?		NV;qcoFRPzJiaB?=	Mn3Vd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu	MYCyNlU3OjF4MB?=
NCCIT	M2X3W2Z2dmO2aX;uJGF{e2G7		MV23NkBp	NIrj[FR{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhSmOuLUKgZ49vfGWwdB?=	NH\Le4UzOjV4MkG2NC=>
NCCIT	NHuxUHJHfW6ldHnvckBCe3OjeR?=		MVq3NkBp	MVHzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgR5l1NWNibHX2[Yw>	MljONlI2PjJzNkC=
HeLa	M2juZmZ2dmO2aX;uJGF{e2G7	M2DJb\|MxNzdyIN88[{9udA>?	MoLRNlTDqGh?	MlLEbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV\|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU>	MkXMNlI1QDd7M{e=
MCF-7	M2nmdmZ2dmO2aX;uJGF{e2G7	NGWxbYI{OC95MDFOwIcwdWx?	MV:yOOKhcA>?	NFnlVGNqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>?	NIf4fm4zOjR6N{mzOy=>
HeLa	MmD3R5l1d3SxeHnjbZR6KEG\|c3H5	MXSzNE84OCEQvHevcYw>	MoHaNlTDqGh?	M3TPfolv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG\|bR?=	NYTDcWYxOjJ2OEe5N\|c>
MCF-7	MVHDfZRwfG:6aXPpeJkhSXO\|YYm=	M2T4UlMxNzdyIN88[{9udA>?	MYmyOOKhcA>?	MlexbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy\|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv	NH7a[ZozOjR6N{mzOy=>
NT2	M3fIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjDVnVEOTByLU[wNOKh\|rypL33s	M{XhWlI1KGh?	NVLVdmFpUUN3ME20NFAhyrWpL33s	M4CycFIzPDZ7OUWy
NT2	MV3GeY5kfGmxbjDBd5NigQ>?	M2Dwb\|QxOMLizsznM41t	MnnPNlQhcA>?	NIfD[2Z{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB?	NIiweVEzOjR4OUm1Ni=>
NT2	NFTo[mFHfW6ldHnvckBCe3OjeR?=	NU\6[Ho3PDBywrFOwIcwdWx?	MoSxNlQhcA>?	Ml7Ed4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu	NXHGNJJHOjJ2Nkm5OVI>
NT2	MVfGeY5kfGmxbjDBd5NigQ>?	NFficY01ODEEoN88[{9udA>?	MUGyOEBp	MYfzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?=	MmTONlI1Pjl7NUK=
CHO	MXrGeY5kfGmxbjDBd5NigQ>?	MUCyMlXDqM7:Zz;tcC=>	MWqxPEBpNzZiZB?=	NIDoZ4NqdmS3Y3XzxsBx\XK\|aYP0[Y5k\SCxZjDjbJJwdW:\|b33lJIRidWGpZR?=	M{HMOlIzOjNyMUm1
Jurkat	NU\mZYhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTVWnd5OC1zMEFCpO69\y:vbB?=	M3GwSVI1KGh?	MkT5ZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U>	MkjsNlIzOjN\|M{K=
Jurkat	NV7xU2c2TnWwY4Tpc44hSXO\|YYm=	M3HJW\|MxyqEQvHevcYw>	NInuNoczPCCq	NUTiW2ZNcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6\|IFSzMEBCKGGwZDDCNS=>	NXn0VmczOjJ{MkOzN\|I>
Jurkat	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF[zU2IxNTFyMNMg{txoN22u	MVWyOEBp	MmXFbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx?	M{XsWFIzOjJ\|M{Oy
Jurkat	MXnGeY5kfGmxbjDBd5NigQ>?	MU[zNOKh\|rypL33s	Ml2yNlQhcA>?	M3v6XIlv[3KnYYPld{B1cGViZX\m[YN1KG:oIID5Z45q\GmxbnWgc44heGixc4Doc5J6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGgzSS6[	MYGyNlIzOzN\|Mh?=
U2OS EGFPnls	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLrNE0zyqEQvHevcYw>	M2[xOVI1KGh?	MY\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NXfNbIx7OjF6MUGwNFc>
U2OS KuEnls	NWfWOlBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7kZlVjOC1{wrFOwIcwdWx?	NYL3T3ljOjRiaB?=	Ml3NbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M3vFVFIyQDFzMEC3
MCF-7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi5UocxNTRyMDFOwG0>	NFz2TIk4OiCq	NXzVNm5VVEN3ME2xOVEvQMLizszN	NXzsPYwyOjF5MEOyPVE>
MCF-7/Adr	NFXLd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW0SY0xNTRyMDFOwG0>	Mme5O\|IhcA>?	NECxeG9NSzVyPUW4MlXDqM7:TdMg	NHSwWYgzOTdyM{K5NS=>
WI-38	NWm3O2h1TnWwY4Tpc44hSXO\|YYm=	MX:wM\|QxNzhy4pEJ{txoN22uwrC=	M{P5V\|MhcA>?	M1T4PIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA>	M1rD[lIyPTl7NkGy
hBMSC	NUHXcZRkTnWwY4Tpc44hSXO\|YYm=	MlHCNE81OC96MPMAje69\y:vbNMg	MnO1N{Bp	M13VXIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG\|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA>	M{fROFIyPTl7NkGy
NCI-H23	NHLJR41HfW6ldHnvckBCe3OjeR?=	Mnn3NE81OC96MPMAje69\y:vbNMg	M2jEblMhcA>?	NFvFeVVqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh	MX6yNVU6QTZzMh?=
A-549	NWX3e2xOTnWwY4Tpc44hSXO\|YYm=	MX2wM\|QxNzhy4pEJ{txoN22uwrC=	MVOzJIg>	NYn6XnhTcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>?	M2HW[\|IyPTl7NkGy
PBL	MYnGeY5kfGmxbjDBd5NigQ>?	M13jR\|AwPDBxOEFihKnPxGdxbX\|CpC=>	NF3ENms{KGh?	MWTpcoR2[2W\|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg	MXiyNVU6QTZzMh?=
pol β −/−	NFW5XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nlW\|AvOjVvMkCwxsDPxGdxbXy=	MU[yOOKhcA>?	Mlq0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh	MWiyNVI2OTl2NB?=
pol β +/+	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q2TVAvOjVvMkCwxsDPxGdxbXy=	MX6yOOKhcA>?	M4HtWYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bZRpKGmwY4LlZZNqdmdiY3;uZ4VvfHKjdHnvcpPDqA>?	NIfuT2MzOTJ3MUm0OC=>
pol β −/−	MVnGeY5kfGmxbjDBd5NigQ>?	M4f5dlAuOi53IN88[{9udA>?	NHTDS4YzKGh?	NF7FWpNk[XW\|ZYOgSG5CKGSjbXHn[S=>	NXHTenZxOjF{NUG5OFQ>
pol β +/+	MWHGeY5kfGmxbjDBd5NigQ>?	M1z4ZlAuOi53IN88[{9udA>?	MmfONkBp	NUPxOWt3[2G3c3XzJGRPSSCmYX3h[4U>	MWSyNVI2OTl2NB?=
pol β −/−	MYjGeY5kfGmxbjDBd5NigQ>?	NYT4VlNVOC13IN88[{9udA>?	MYW0PEBp	NViyZ3Jo[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6	NVHMemtsOjF{NUG5OFQ>
pol β +/+	M3j3fmZ2dmO2aX;uJGF{e2G7	M4fMOVAuPSEQvHevcYw>	NWnDZ2N2PDhiaB?=	MYXjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	NWfJTJJvOjF{NUG5OFQ>
TK6	NXLxPWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDM[FUzPS1zNUCg{txoN22u	MljaPVYhcA>?	M3XtSolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	M1zhbVIyODhzNEi3
TK6 sLUC+Apn1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LKNFI2NTF3MDFOwIcwdWx?	M3fPXVk3KGh?	MkfpbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M3roc\|IyODhzNEi3
TK6 sAPE1+Apn1	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvKfIgzPS1zNUCg{txoN22u	Mm\CPVYhcA>?	Mn\ad4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7	MnLCNlExQDF2OEe=
HCT116	NXP5TGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrDd5QzPS1zNUCg{txoN22u	NHqwcHo6PiCq	MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	MW[yNVA5OTR6Nx?=
HCT116 sLUC+Apn1	NETOPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LIT\|I2NTF3MDFOwIcwdWx?	MnG2PVYhcA>?	MUnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	NE\oOGIzOTB6MUS4Oy=>
HCT116 sAPE1+Apn1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DWc\|I2NTF3MDFOwIcwdWx?	NUXUWmZzQTZiaB?=	NWDBUYZwe2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	Mn7uNlExQDF2OEe=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	LRP6 / Wnt5AB / Dvl2 / β-catenin; PubMed: 27649046 J Cell Physiol CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. phospho-eIF2α / eIF2α; PubMed: 23762310 PLoS One Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin cytochrome c; PubMed: 20154224 Am J Physiol Lung Cell Mol Physiol mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown. Bcl-xl; PubMed: 20154224 Am J Physiol Lung Cell Mol Physiol Representative Western blots are shown of whole cell extract using anti-Bcl-xL. Bcl-2; PubMed: 20154224 Am J Physiol Lung Cell Mol Physiol Representative Western blots are shown of whole cell extract using anti-Bcl-2.	27649046 23762310 20154224
Immunofluorescence	LC3; PubMed: 23762310 PLoS One CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin	23762310
ELISA	HMGB1; PubMed: 23762310 PLoS One HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin	23762310

体内試験

Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. ^[5]

お薦めの試験操作（参考用のみ）

細胞試験： ^[4]	- 合併細胞株： ADIPO-P2 cells 濃度： 2.5 μg/mL 反応時間： 30 minutes 実験の流れ： ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO₂ atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 10⁵ cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 10⁵ cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 10⁵ cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out. (参考用のみ)
動物試験： ^[7]	- 合併動物モデル： CD-1 mice 投薬量： 5 mg/kg, 2 ml/kg 投与方法： Administered via i.t. (参考用のみ)

細胞試験：

^[4]

- 合併

細胞株： ADIPO-P2 cells
濃度： 2.5 μg/mL
反応時間： 30 minutes
実験の流れ：
ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO₂ atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 10⁵ cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 10⁵ cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 10⁵ cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.

(参考用のみ)

動物試験：

^[7]

- 合併

動物モデル： CD-1 mice
投薬量： 5 mg/kg, 2 ml/kg
投与方法： Administered via i.t.
(参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	100 mg/mL (66.11 mM) warming
	Water	100 mg/mL (66.11 mM)
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): Saline 混合させたのち直ちに使用することを推奨します。	30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Bleomycin Sulfate SDFをダウンロードする

分子量	1512.62
化学式	C₅₅H₈₅N₁₇O₂₅S₄
CAS No.	9041-93-4
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	NSC125066
Smiles	CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)C1=C(C)C(=NC(=N1)C(CC(N)=O)NCC(N)C(N)=O)N)C(OC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(OC(N)=O)C3O)C4=C[NH]C=N4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.O[S]([O-])

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
what is the ratio between bleomycin A2 and bleomycin B2 in your product?
回答：
The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

研究分野別

製品類型

Bleomycin Sulfate

文献中Selleckの製品使用例(36)

質量管理及び製品安全説明書

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Bleomycin Sulfate SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

技術サポート

よくある質問（FAQ）